TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04793880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Cost Information
Description: This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Medicines Checklist
Description: The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Medicines Checklist
Description: The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
Study: NCT05268471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional device (PD)
Description: OSA treatment with PD for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuos Positive Airway Pressure (CPAP)
Description: OSA treatment with CPAP for 6 months
Study: NCT05613439

Intervention type: PROCEDURE
Intervention: Day-surgery
Description: Standard surgical procedure but with planned discharge on day of surgery

Intervention type: PROCEDURE
Intervention: High-risk patient
Description: Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.

Intervention type: PROCEDURE
Intervention: Main Group
Description: Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
Study: NCT04983394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Realty Exercises
Description: motion-controlled video game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: cycling activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: stretching, strengthening and endurance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional exercises
Description: stretching, strengthening and endurance exercises
Study: NCT06013423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Receive IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Receive IV or PO
Study: NCT04844385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240 mg, d1, Q3w for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240 mg, d1, Q3w for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
Study: NCT06013423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Receive IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Receive IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high-dose or middle-intensity TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high-dose or middle-intensity TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT
Study: NCT06180174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC-1-50
Description: A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
Study: NCT04999137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
Study: NCT04756167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Hotpack, TENS, ultrasound and exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Treatment
Description: Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
Study: NCT05286931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin 500 MG, taken once orally.
Study: NCT06538844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human albumin
Description: Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
Study: NCT04844385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 75mg/m2, d1, Q3w for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 75mg/m2, d1, Q3w for two cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy at a total dose 60 Gy
Description: Radiation therapy at a total dose 60 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy at a total dose 50 Gy
Description: Radiation therapy at a total dose 50 Gy
Study: NCT05040763

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Buccal Swabc- Copan flocked swab
Description: All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of Care COVID-19 swab
Description: All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
Study: NCT06538844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Equivalent volume of isotonic saline control
Study: NCT05524389

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: High-dose rate vaginal brachytherapy (VBT) was delivered with a vaginal cylinder.For VBT administered alone, the dose is recommended: 3 fractions of 7 Gy or 5 fractions of 6 Gy or 6 fractions of 5 Gy.~For VBT administered after completion of EBRT: 2-3 fractions of 4-6 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: High-dose rate vaginal brachytherapy (VBT) was delivered with a vaginal cylinder.For VBT administered alone, the dose is recommended: 3 fractions of 7 Gy or 5 fractions of 6 Gy or 6 fractions of 5 Gy.~For VBT administered after completion of EBRT: 2-3 fractions of 4-6 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic external beam radiotherapy
Description: EBRT was delivered to the pelvic area using a total dose of 45-50.4Gy in 25-28 fractions over 5-6 weeks with the intensity-modulated radiotherapy (IMRT) technique, three-dimensional conformal radiotherapy (3D-CRT) modality
Study: NCT05164705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia
Description: Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia
Description: Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
Study: NCT05524389

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiotherapy
Description: EBRT was delivered to the pelvic area using a total dose of 45-50.4Gy in 25-28 fractions over 5-6 weeks with the intensity-modulated radiotherapy (IMRT) technique, three-dimensional conformal radiotherapy (3D-CRT) modality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No radiotherapy is administrated, but active follow-up and quality of life questionnaires is needed after surgery.
Study: NCT05756647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Arm
Description: The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment Arm
Description: Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
Study: NCT00764348

Intervention type: OTHER
Intervention: no treatment
Study: NCT06165068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Patients take aspirin 81 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: Patients take aspirin 81 mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients take clopidogrel 75 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients take clopidogrel 75 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients are given N-acetylcysteine 600 mg per day.
Study: NCT05731219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7-H3 target, CAR gene modified gdT cell injection
Description: After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
Study: NCT05757375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Manuel Therapy Consept
Description: Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Manuel Therapy Consept
Description: Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
Study: NCT06309875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLAN CUIDARTE
Description: Description Plan Cuidarte

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Description Conventional care
Study: NCT06127134

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: peripheral angioplasty for tibial vessels
Description: repair tibials blood vessels throughout two concepts using angioplasty ballooning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral angioplasty for tibial vessels
Description: repair tibials blood vessels throughout two concepts using angioplasty ballooning
Study: NCT06209112

Intervention type: DRUG
Intervention: Sevoflurane
Description: The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.

Intervention type: DRUG
Intervention: Sevoflurane
Description: The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
Study: NCT04959084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy and pelvic floor training
Description: The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
Study: NCT06442527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality gear and content will be used prior to TMS session as part of the provocation items
Study: NCT05524389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
Study: NCT05920304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual Hospital at Home (vHaH)
Description: Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app.
Study: NCT06205862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: We will use fecal suspensions and capsules prepared from the feces of healthy donors for fecal microbiota transplantation. Participants are required to complete one colonoscopy and infuse 150ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 2 days continuously (day 1-2), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules (20 capsules bid) at 3, 6, and 9 months (approximately every 75 to 90 days). Participants will undergo their first follow-up colonoscopy between 6 to 12 months(the high-risk adenoma group will receive colonoscopy at 6 months, and the low-risk adenoma group will receive colonoscopy at 12 months).
Study: NCT05425212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional activation with kinesio tapping
Description: These exercises will be carried out thrice a week for 4 weeks. The exercises will be performed for approximately 35-45 minutes, 1 to 2 times a day, in sitting or standing position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; 4 days a week for 4 weeks
Study: NCT05853237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy for wound management
Description: comparison between laser effect on post median sternotomy incision compared to traditional wound care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy for wound management
Description: comparison between laser effect on post median sternotomy incision compared to traditional wound care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy for wound management
Description: comparison between laser effect on post median sternotomy incision compared to traditional wound care
Study: NCT05717972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kombucha
Description: Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste.

Intervention type: OTHER
Group type: OTHER
Intervention: Kombucha
Description: Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste.
Study: NCT06533605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-706
Description: Bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-706
Description: Bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-706
Description: Bispecific antibody
Study: NCT04797637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABBy® Adjustable Panniculus Retractor for Wound Care
Description: The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
Study: NCT04793815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo-activation
Description: The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
Study: NCT06533605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-706
Description: Bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-706
Description: Bispecific antibody
Study: NCT06716970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200mg placebo
Description: Matching placebo of Sacubitril/valsartan 200mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200mg placebo
Description: Matching placebo of Sacubitril/valsartan 200mg QD
Study: NCT06716281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride Injection
Study: NCT06719895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based education
Description: experimental
Study: NCT06720792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EscapeCovid
Description: Online Escape Game with 4 players and a game guide. The players, in a group, must solve enigmas to win.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EscapeCovid
Description: Online Escape Game with 4 players and a game guide. The players, in a group, must solve enigmas to win.